{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:21Z","timestamp":1790706981220,"version":"4.1.0"},"reference-count":14,"publisher":"Massachusetts Medical Society","issue":"11","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Orion Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2020,9,10]]},"DOI":"10.1056\/nejmoa2001342","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T17:02:06Z","timestamp":1599670926000},"page":"1040-1049","source":"Crossref","is-referenced-by-count":332,"title":["Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide"],"prefix":"10.1056","volume":"383","author":[{"given":"Karim","family":"Fizazi","sequence":"first","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.","family":"Tammela","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertas","family":"Ulys","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egils","family":"Vjaters","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Polyakov","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindaugas","family":"Jievaltas","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo","family":"Luz","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Alekseev","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kuss","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aude","family":"Le Berre","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Petrenciuc","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Snapir","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Sarapohja","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"From Institut Gustave Roussy, University of Paris-Saclay, Villejuif (K.F.), and Bayer Healthcare SAS, Loos (M.-A.L.B.) \u2014 both in France; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and Tampere University, Tampere (T.L.T.), and Orion Pharma, Espoo (A.S., T.S.) \u2014 both in Finland; the National Cancer Institute, Vilnius (A.U.), and the Lithuanian University of Health Sciences, Medical Academy, Kaunas (M.J.) \u2014 both in Lithuania; Stradins Clinical University..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"e_1_3_5_3_2","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer. 2020 (http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf)."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6716"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.4"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.07.035"},{"key":"e_1_3_5_7_2","unstructured":"Nubeqa (darolutamide): prescribing information. 2019 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf)."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815671"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.11.007"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546"},{"key":"e_1_3_5_12_2","unstructured":"Department of Health and Human Services National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 2010 (https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)."},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.156"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.326","article-title":"Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.","volume":"38","author":"Williams S","year":"2020","unstructured":"Williams S, Mazibuko N, O\u2019Daly O, et al. Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. J Clin Oncol 2020;38:6 Suppl:326. abstract.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz397"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2001342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:15:09Z","timestamp":1711487709000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,9,10]]}},"alternative-id":["10.1056\/NEJMoa2001342"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2001342","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}